Loading the session
Loading the session
Loading instrument
$250.00
+7.28%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:51 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $246.70 on 4 Nov 2026: 3.3% below the 52-week high of $255.19 (4 Nov 2026) and 204.9% above the low of $80.91 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +52.7% (SPY −1.6%, XLV +13.5%). 3 months: +44.3% (SPY −0.4%, XLV +15.5%). 1 year: +187.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GKOS, SPY and XLV · as of 4 Nov 2026
3 Nov 2026 volume of 10.7M shares was 8.6× the average of the 30 sessions before it (1.3M), as the price fell 2.3%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
The 14-session relative strength index closed at 80.8 on 4 Nov 2026, its 5th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
The 4 Nov 2026 close of $246.70 was 39.7% above its 50-day average ($176.62) and 72.2% above its 200-day average ($143.25). It has closed above the 200-day for 109 sessions, since 2 Jun 2026. The 50-day average crossed above the 200-day on 19 Dec 2025, 219 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
October 29, 2026
+33.65%April 30, 2026
+22.84%December 14, 2023
+25.36%